Lima1, also known as EPLIN or SREBP3, is a LIM domain and actin-binding protein. It functions as a key regulator in multiple biological processes. In the context of lipid metabolism, it promotes cholesterol absorption, especially in the small intestine [1,3]. It is also involved in processes related to the actin cytoskeleton, cell motility, and cell-cell adhesion, and has emerging roles in cell division, gene regulation, and metabolism [2].

In mouse models, Lima1-deficient mice displayed reduced cholesterol absorption and were resistant to diet-induced hypercholesterolemia, identifying Lima1 as a key protein regulating intestinal cholesterol absorption [1]. In the context of non-alcoholic fatty liver disease (NAFLD), lipotoxic hepatocyte-derived Lima1-enriched small extracellular vesicles promoted hepatic stellate cells activation via inhibiting mitophagy in mice [4].

In conclusion, Lima1 is crucial for lipid metabolism, especially intestinal cholesterol absorption. Mouse models, such as Lima1-deficient mice, have revealed its role in cholesterol-related diseases like diet-induced hypercholesterolemia and in liver-related conditions such as NAFLD-associated fibrosis. These findings contribute to understanding the underlying mechanisms of these diseases and may offer potential therapeutic targets.